Search

Your search keyword '"Szarewski, A"' showing total 694 results
Start Over Author "Szarewski, A"
694 results on '"Szarewski, A"'

1. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism

Author

Bitzer, Johannes, Amy, Jean-Jacques, Beerthuizen, Rob, Birkhäuser, Martin, Bombas, Teresa, Creinin, Mitchell, Darney, Philip D, Vicente, Lisa Ferreira, Gemzell-Danielsson, Kristina, Imthurn, Bruno, Jensen, Jeffrey T, Kaunitz, Andrew M, Kubba, Ali, Lech, Medard M, Mansour, Diana, Merki, Gabriele, Rabe, Thomas, Sedlecki, Katarina, Serfaty, David, Seydoux, Jacques, Shulman, Lee P, Sitruk-Ware, Regine, Skouby, Sven O, Szarewski, Anne, Trussell, James, and Westhoff, Carolyn

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Contraceptives, Oral, Combined, Contraceptives, Oral, Hormonal, Cyproterone Acetate, Europe, Female, Humans, Progestins, Risk Assessment, Venous Thromboembolism, Women's Health, Reproductive medicine, Public health
Published
2013

2. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Author

Skinner, S Rachel, Szarewski, Anne, Romanowski, Barbara, Garland, Suzanne M, Lazcano-Ponce, Eduardo, Salmerón, Jorge, Del Rosario-Raymundo, M Rowena, Verheijen, René H M, Quek, Swee Chong, da Silva, Daniel P, Kitchener, Henry, Fong, Kah Leng, Bouchard, Céline, Money, Deborah M, Ilancheran, Arunachalam, Cruickshank, Margaret E, Levin, Myron J, Chatterjee, Archana, Stapleton, Jack T, Martens, Mark, Quint, Wim, David, Marie-Pierre, Meric, Dorothée, Hardt, Karin, Descamps, Dominique, Geeraerts, Brecht, Struyf, Frank, and Dubin, Gary

Published
2014
Full Text
View/download PDF

3. Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

Author

Castellsagué, Xavier, Naud, Paulo, Chow, Song-Nan, Wheeler, Cosette M., Germar, Maria Julieta V., Lehtinen, Matti, Paavonen, Jorma, Jaisamrarn, Unnop, Garland, Suzanne M., Salmerón, Jorge, Apter, Dan, Kitchener, Henry, Teixeira, Julio C., Skinner, S. Rachel, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y., Schwarz, Tino F., Poppe, Willy A. J., Bosch, F. Xavier, de Carvalho, Newton S., Peters, Klaus, Tjalma, Wiebren A. A., Safaeian, Mahboobeh, Raillard, Alice, Descamps, Dominique, Struyf, Frank, Dubin, Gary, Rosillon, Dominique, and Baril, Laurence

Published
2014

4. Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

Author

Szarewski, Anne, Skinner, S. Rachel, Garland, Suzanne M., Romanowski, Barbara, Schwarz, Tino F., Apter, Dan, Chow, Song-Nan, Paavonen, Jorma, Del Rosario-Raymundo, M. Rowena, Teixeira, Julio C., De Carvalho, Newton S., Castro-Sanchez, Maria, Castellsagué, Xavier, Poppe, Willy A. J., De Sutter, Philippe, Huh, Warner, Chatterjee, Archana, Tjalma, Wiebren A., Ackerman, Ronald T., Martens, Mark, Papp, Kim A., Bajo-Arenas, Jose, Harper, Diane M., Torné, Aureli, David, Marie-Pierre, Struyf, Frank, Lehtinen, Matti, and Dubin, Gary

Published
2013
Full Text
View/download PDF

6. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial

Author

Roset Bahmanyar, Edith, Paavonen, Jorma, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Apter, Dan, Kitchener, Henry, Castellsagué, Xavier, Teixeira, Julio C., Skinner, S. Rachel, Jaisamrarn, Unnop, Limson, Genara A., Garland, Suzanne M., Szarewski, Anne, Romanowski, Barbara, Aoki, Fred, Schwarz, Tino F., Poppe, Willy A.J., De Carvalho, Newton S., Harper, Diane M., Bosch, F. Xavier, Raillard, Alice, Descamps, Dominique, Struyf, Frank, Lehtinen, Matti, and Dubin, Gary

Published
2012
Full Text
View/download PDF

7. Women’s perceptions about reducing the frequency of monthly bleeding: results from a multinational survey

Author

Szarewski A and Moeller C

Subjects
Gynecology and obstetrics, RG1-991
Abstract

Anne Szarewski,1 Cecilia Moeller2 1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; 2Bayer HealthCare Pharmaceuticals, Global Market Research General Medicine, Berlin, Germany Background: Monthly bleeding can have a negative impact on daily life and, given the choice, many women would reduce the frequency of bleeding. While some women choose to occasionally postpone or reduce bleeding frequency with an oral contraceptive (OC), most women have no or limited experience of regularly reducing the frequency of scheduled bleeding with OCs, ie, the extended OC regimen. Study design: An online survey of 4039 women aged 15–49 years who were currently using, had used, or would consider using any form of hormonal contraception was conducted in Brazil, Canada, Czech Republic, France, Germany, Italy, UK, and USA to assess awareness of and the reasons for and against reducing bleeding frequency. Results: Overall, 51.1% and 30.7% of women surveyed were aware that they could occasionally or regularly reduce bleeding frequency with an OC. Moreover, 27.6% and 9.9% of previous/current OC users had occasionally or regularly reduced bleeding frequency with an OC. The main reasons for reducing bleeding frequency were convenience, physician recommendations, special events, and relief of problems associated with bleeding. Many women mistakenly believed that reducing bleeding frequency would have a negative health impact. Conclusion: Additional efforts are needed to educate women about the possibility and potential health benefits of reducing bleeding frequency and to dispel misconceptions about the use of extended OC regimens. Keywords: extended regimen, menstruation, oral contraceptive, withdrawal bleeding, scheduled bleeding

Published
2013

8. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Author

Wheeler, Cosette M, Castellsagué, Xavier, Garland, Suzanne M, Szarewski, Anne, Paavonen, Jorma, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Apter, Dan, Kitchener, Henry, Teixeira, Júlio C, Skinner, S Rachel, Jaisamrarn, Unnop, Limson, Genara, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, Poppe, Willy A J, Bosch, F Xavier, Harper, Diane M, Huh, Warner, Hardt, Karin, Zahaf, Toufik, Descamps, Dominique, Struyf, Frank, Dubin, Gary, and Lehtinen, Matti

Published
2012
Full Text
View/download PDF

9. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Author

Lehtinen, Matti, Paavonen, Jorma, Wheeler, Cosette M, Jaisamrarn, Unnop, Garland, Suzanne M, Castellsagué, Xavier, Skinner, S Rachel, Apter, Dan, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Kitchener, Henry, Teixeira, Júlio C, Hedrick, James, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, Poppe, Willy A J, De Carvalho, Newton S, Germar, Maria Julieta V, Peters, Klaus, Mindel, Adrian, De Sutter, Philippe, Bosch, F Xavier, David, Marie-Pierre, Descamps, Dominique, Struyf, Frank, and Dubin, Gary

Published
2012
Full Text
View/download PDF

13. Mortality Associated with Oral Contraceptive Use

Author

Szarewski, Anne, Kitchener, Henry C., Horowitz, Joseph, Kahlenborn, Chris, Grant, Ellen C. G., Steel, C. Michael, Price, Elizabeth H., Anthony, Honor M., Downing, Damien, Radcliffe, Michael J., and Myhill, Sarah

Published
1999

15. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Author

Paavonen, J, Naud, P, Salmerón, J, Wheeler, CM, Chow, S-N, Apter, D, Kitchener, H, Castellsague, X, Teixeira, JC, Skinner, SR, Hedrick, J, Jaisamrarn, U, Limson, G, Garland, S, Szarewski, A, Romanowski, B, Aoki, FY, Schwarz, TF, Poppe, WAJ, Bosch, FX, Jenkins, D, Hardt, K, Zahaf, T, Descamps, D, Struyf, F, Lehtinen, M, and Dubin, G

Published
2009
Full Text
View/download PDF

18. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.

Author

Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, Paulo Naud, Johanna Palmroth, Maria Rowena Del Rosario-Raymundo, Cosette M Wheeler, Jorge Salmerón, Song-Nan Chow, Dan Apter, Julio C Teixeira, S Rachel Skinner, James Hedrick, Anne Szarewski, Barbara Romanowski, Fred Y Aoki, Tino F Schwarz, Willy A J Poppe, F Xavier Bosch, Newton S de Carvalho, Maria Julieta Germar, Klaus Peters, Jorma Paavonen, Marie-Cecile Bozonnat, Dominique Descamps, Frank Struyf, Gary O Dubin, Dominique Rosillon, Laurence Baril, and HPV PATRICIA Study Group

Subjects
Medicine, Science
Abstract

BackgroundThe control arm of PATRICIA (PApilloma TRIal against Cancer In young Adults, NCT00122681) was used to investigate the risk of progression from cervical HPV infection to cervical intraepithelial neoplasia (CIN) or clearance of infection, and associated determinants.Methods and findingsWomen aged 15-25 years were enrolled. A 6-month persistent HPV infection (6MPI) was defined as detection of the same HPV type at two consecutive evaluations over 6 months and clearance as ≥2 type-specific HPV negative samples taken at two consecutive intervals of approximately 6 months following a positive sample. The primary endpoint was CIN grade 2 or greater (CIN2+) associated with the same HPV type as a 6MPI. Secondary endpoints were CIN1+/CIN3+ associated with the same HPV type as a 6MPI; CIN1+/CIN2+/CIN3+ associated with an infection of any duration; and clearance of infection. The analyses included 4825 women with 16,785 infections (3363 women with 6902 6MPIs). Risk of developing a CIN1+/CIN2+/CIN3+ associated with same HPV type as a 6MPI varied with HPV type and was significantly higher for oncogenic versus non-oncogenic types. Hazard ratios for development of CIN2+ were 10.44 (95% CI: 6.96-15.65), 9.65 (5.97-15.60), 5.68 (3.50-9.21), 5.38 (2.87-10.06) and 3.87 (2.38-6.30) for HPV-16, HPV-33, HPV-31, HPV-45 and HPV-18, respectively. HPV-16 or HPV-33 6MPIs had ~25-fold higher risk for progression to CIN3+. Previous or concomitant HPV infection or CIN1+ associated with a different HPV type increased risk. Of the different oncogenic HPV types, HPV-16 and HPV-31 infections were least likely to clear.ConclusionsCervical infections with oncogenic HPV types increased the risk of CIN2+ and CIN3+. Previous or concomitant infection or CIN1+ also increased the risk. HPV-16 and HPV-33 have by far the highest risk of progression to CIN3+, and HPV-16 and HPV-31 have the lowest chance of clearance.

Published
2013
Full Text
View/download PDF

19. Correction: Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study.

Author

Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M. Garland, Paulo Naud, Johanna Palmroth, Maria Rowena Del Rosario-Raymundo, Cosette M. Wheeler, Jorge Salmerón, Song-Nan Chow, Dan Apter, Julio C. Teixeira, S. Rachel Skinner, James Hedrick, Anne Szarewski, Barbara Romanowski, Fred Y. Aoki, Tino F. Schwarz, Willy A. J. Poppe, F. Xavier Bosch, Newton S. de Carvalho, Maria Julieta Germar, Klaus Peters, Jorma Paavonen, Marie-Cecile Bozonnat, Dominique Descamps, Frank Struyf, Gary O. Dubin, Dominique Rosillon, and Laurence Baril

Subjects
Medicine, Science
Published
2013
Full Text
View/download PDF

22. Contraception

Author

Szarewski, Anne and Hope, Sally

Subjects
Contraceptive drugs -- Usage, Family medicine -- Analysis -- Usage, Business, Health, Health care industry, Business, international, Levonelle (Contraceptive) -- Usage
Abstract

Summary An evidence-based patient choice approach to contraception, assisting the patient to choose the contraceptive method she feels most comfortable with at this moment of her life, will provide high [...]

Published
2006

25. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18

Author

Szarewski, A., Poppe, W. A.J., Skinner, S. R., Wheeler, C. M., Paavonen, J., Naud, P., Salmeron, J., Chow, S.-N., Apter, D., Kitchener, H., Castellsagué, X., Teixeira, J. C., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Romanowski, B., Aoki, F. Y., Schwarz, T. F., Bosch, F. X., Harper, D. M., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., and Dubin, G.

Published
2012
Full Text
View/download PDF

31. Exploring the acceptability of two self-sampling devices for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in London

Author

Szarewski, Anne, Cadman, Louise, Ashdown-Barr, Lesley, and Waller, Jo

Subjects
Cervical cancer -- Diagnosis, Cervical cancer -- Research, Women, Muslim -- Beliefs, opinions and attitudes, Health attitudes -- Research, Focus groups -- Surveys, Self-examination, Medical -- Research, Cancer -- Diagnosis, Cancer -- Demographic aspects, Cancer -- Research, Health, Social sciences
Published
2009

36. Public awareness of human papillomavirus

Author

Cuschieri, K.S., Horne, A.W., Szarewski, A., and Cubie, H.A.

Subjects
Papillomavirus infections -- Research, Papillomavirus infections -- Diagnosis, Papillomavirus infections -- Care and treatment, Papillomavirus infections -- Social aspects, Public health -- Management, Health education -- Social aspects, Health education -- Management, Company business management, Health, Social sciences
Published
2006

37. Acceptability of unsupervised HPV self-sampling using written instructions

Author

Waller, J., McCaffery, K., Forrest, S., Szarewski, A., Cadman, L., Austin, J., and Wardle, J.

Subjects
Papillomavirus infections -- Diagnosis, Cervical cancer -- Diagnosis, Cervical cancer -- Research, Women -- Health aspects, Women -- Research, Self-examination, Medical -- Research, Self-examination, Medical -- Health aspects, Health, Social sciences
Published
2006

50. Human papillomavirus testing in primary cervical screening

Author

Cuzick, J., Szarewski, A., Terry, G., Ho, L., Hanby, A., Maddox, P., Anderson, M., Kocjan, G., Steele, S.T., and Guillebaud, J.

Subjects
Papillomavirus infections -- Testing, Cervix dysplasia -- Diagnosis
Published
1995

Catalog

Books, media, physical & digital resources
See catalog results